Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01984801




Registration number
NCT01984801
Ethics application status
Date submitted
5/09/2013
Date registered
15/11/2013
Date last updated
9/05/2017

Titles & IDs
Public title
Study to Investigate the Irritation Potential of GSK1940029 Gel
Scientific title
A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients
Secondary ID [1] 0 0
117225
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acne Vulgaris 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 0.3% GSK1940029 gel
Treatment: Drugs - 1% GSK1940029 gel
Treatment: Drugs - 0.3%/1% vehicle gel only
Other interventions - Sterile distilled water
Other interventions - 0.5% SLS in sterile distilled water
Other interventions - 0.1% SLS in sterile distilled water
Other interventions - Patch only

Experimental: Part 1 - Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days

Experimental: Part 2 - Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days

Experimental: Part 3 - Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days


Treatment: Drugs: 0.3% GSK1940029 gel
200 mg of the gel will be applied to individual patches by using a spatula

Treatment: Drugs: 1% GSK1940029 gel
200 mg of the gel will be applied to individual patches by using a spatula

Treatment: Drugs: 0.3%/1% vehicle gel only
200 mg of the gel will be applied to individual patches by using a spatula

Other interventions: Sterile distilled water
200 µL of the solution will be applied to individual patches by using a pipette or syringe

Other interventions: 0.5% SLS in sterile distilled water
200 µL of the solution will be applied to individual patches by using a pipette or syringe

Other interventions: 0.1% SLS in sterile distilled water
200 µL of the solution will be applied to individual patches by using a pipette or syringe

Other interventions: Patch only
Only patch will be applied
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary cutaneous irritation scores
Timepoint [1] 0 0
Days 2, 3 4 and 5 of Part 1
Primary outcome [2] 0 0
Cumulative cutaneous irritation scores
Timepoint [2] 0 0
Day 2 to Day 22 of Part 2
Primary outcome [3] 0 0
Facial irritation scores
Timepoint [3] 0 0
Days 1, 7, 14, 21, 28, 29 and at FU (Days 35-42) of Part 3
Primary outcome [4] 0 0
Lanman-Maibach irritation classifications
Timepoint [4] 0 0
Day 2 to Day 22 of Part 2
Primary outcome [5] 0 0
Tolerability of GSK1940029 as assessed by Clinical monitoring/observation
Timepoint [5] 0 0
Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Primary outcome [6] 0 0
Tolerability of GSK1940029 as assessed by adverse events (AEs)
Timepoint [6] 0 0
Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Secondary outcome [1] 0 0
Safety and tolerability of GSK1940029 as assessed by clinical laboratory tests
Timepoint [1] 0 0
Screening, Days 1, 4, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 8, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Secondary outcome [2] 0 0
Safety and tolerability of GSK1940029 as assessed by vital signs measurements
Timepoint [2] 0 0
Screening, Days 1, 2, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 2 and FU (Days 29 to 36) of Part 2. Screening, Days 1, 2 and FU (Days 35 to 42) of Part 3
Secondary outcome [3] 0 0
Safety and tolerability of GSK1940029 as assessed by clinical monitoring/observation
Timepoint [3] 0 0
Up to Day 17 of Part 1, Up to Day 36 of Part 2, and Up to Day 42 of Part 3
Secondary outcome [4] 0 0
Ocular tolerability of topical applications of GSK1940029
Timepoint [4] 0 0
Screening, Days 1, 5, and FU (Days 10 to 17) of Part 1. Screening, Days 1, 22, and FU (Days 29 to 36) of Part 2. Screening, Days 1, 7, 14, 21, 29, and FU (Days 35 to 42) of Part 3.
Secondary outcome [5] 0 0
Plasma GSK1940029 pharmacokinetics (PK)
Timepoint [5] 0 0
Part 3 Only - Days 1 and 28: pre-dose, 2, 4, and 8 hours post-dose; Day 2: pre-dose; and Day 29: 24 hour post-Day 28 dose

Eligibility
Key inclusion criteria
- Male or female between 18 and 65 years of age inclusive, at the time of signing the
informed consent.

- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
cardiac monitoring for Parts 1 and 2 only.

- Moderate/Moderate to Severe acne patients, otherwise healthy as determined by a
responsible and experienced physician, based on a medical evaluation including medical
history, physical examination, laboratory tests and cardiac monitoring for Part 3
only.

- A subject with a clinical abnormality or laboratory parameters outside the reference
range for the population being studied may be included only if the Investigator and
the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to
introduce additional risk factors and will not interfere with the study procedures.

- A female subject is eligible to participate if she is of: Non-childbearing potential
defined as pre-menopausal females with a documented tubal ligation or hysterectomy
[for this definition, "documented" refers to the outcome of the
investigator's/designee's review of the subject's medical history for study
eligibility, as obtained via a verbal interview with the subject or from the subject's
medical records]; or postmenopausal defined as 12 months of spontaneous amenorrhea [in
questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH)
> 40 milli international units (MIU)/millilitres (mL) and estradiol <40 picograms
(pg)/mL (<147 picomoles [pmol]/liter [L]) is confirmatory]. Females on hormone
replacement therapy (HRT) and whose menopausal status is in doubt will not be allowed.

- Male subjects with female partners of child-bearing potential must agree to use one of
the contraception methods. This criterion must be followed from the time of the first
dose of study medication until after study follow-up visit.

- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5x upper limit
of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).

- Based on single or averaged assessments, QT duration corrected for heart rate (QTc)
<450 msec; or QTc <480 msec in subjects with bundle branch block.

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome for all study Parts and asymptomatic
gallstones for Parts 1 and 2 only). Subjects with a history of gall stones,
asymptomatic gallstones or cholecystectomy will be excluded.

- A positive pre-study drug/alcohol screen.

- A positive test for Human Immunodeficiency Virus (HIV) antibody.

- History of regular alcohol consumption within 6 months of the study defined as: an
average weekly intake of >14 standard drinks. One standard drink is equivalent to 10
grams (g) of alcohol: 285 mL of beer, 100 mL of wine or 30 mL of 40% alcohol by volume
distilled spirits.

- History of or current meibomian gland dysfunction or dry eye disease

- History or presence of significant skin disorder (such as but not limited to severe
(extensive) atopic dermatitis, severe eczema, psoriasis or skin cancer) that would in
any way confound interpretation of the study results, or subjects who present with
damaged skin including sunburn, moles, uneven skin tones, scar tissue, tattoos, body
piercings, sunburn, branding or other disfiguration on or near the intended site of
application which could interfere with the grading. Acne is allowed for Part 3.

- History of cutaneous photodisorder, such as photoallergic reaction or polymorphic
light eruption. History of cold urticaria and reactions to extreme temperatures.

- History of allergy to soaps, lotions, cosmetics, tape/adhesives, petrolatum or latex
or topical drugs of same class as the study medication.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- History of severe, chronic asthma or significant allergies (including food, drug or
cutaneous allergies). Subjects with the presence or a history of atopy (seasonal
allergies, allergic rhinitis) or mild (limited) eczema will be allowed to participate
in the study, although applications at sites with active eczema will not be allowed.

- Use of topical medications such as but not limited to retinoids, steroids, and
transdermal hormone replacement therapies on or near the intended site of application
within 8 weeks prior to dosing through treatment follow up, for Parts 1 and 2 only or
within 2 weeks period to dosing for Part 3. Use of other topical preparations such as
those containing vitamins, supplements or herbal within 2 weeks prior to dosing
through treatment follow up.

- Unable to refrain from the use of topical medications from the initial dose of study
medication through follow-up.

- Foreseeable intensive Ultraviolet (UV) exposure during the study (solar or artificial)
as follows: subjects must not be exposed to direct sunlight for sun tanning or exposed
to skin tanning devices (e.g. sunbed) for the duration of the study.

- Participation in any patch test for cumulative irritation or sensitization within 4
weeks preceding the first dose of study medication.

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Unable to refrain from the use of prescription or non-prescription drugs, including
vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is
longer) prior to the first dose of study medication, unless in the opinion of the
Investigator and GSK Medical Monitor the medication will not interfere with the study
procedures or compromise subject safety.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

- Unable to refrain from consumption of red wine, seville oranges, grapefruit or
grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit
juices from 7 days prior to the first dose of study medication

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/10/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/04/2015
Sample size
Target
Accrual to date
Final
54
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
GSK Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan
will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and
safety, tolerability and pharmacokinetics of GSK1940029 (Study SCD117226 - 2 Part study),
after topical administration on healthy subjects and acne patients. Study SCD117225 will be a
randomized, single-blind, three part study, to evaluate the primary irritation potential
(Part 1), cumulative irritation potential (Part 2) of two concentrations of GSK1940029 gel
applied to the intact skin of healthy subjects, and the facial irritation potential of one or
two concentrations of GSK1940029 applied to the face of acne patients (Part3). In Part 1 and
Part 2 the following 6 treatments will be applied using individual patches: (A) 200
milligrams (mg) of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of
0.3%/1% vehicle gel only (vehicle control), (D) 200 microliters (µL) of sterile distilled
water (negative irritant control), (E) 200 µL of - 0.5% sodium lauryl sulfate (SLS) in
sterile distilled water for Part 1/0.1% SLS in sterile distilled water for Part 2 (positive
irritant control), and (F) Patch only (patch control). Each treatment will be randomized to
one of six designated locations on either upper arm or other locations, such as the lower or
upper back, within each subject. The same treatment will be reapplied to the same location on
subsequent days. Each treatment will be applied daily for 2 days in Part 1, and daily for 21
days in Part 2. In Part 3, each patient will apply a thin coat of one or two concentration of
GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days.
Parts within Study SCD117225 and Study SCD117226 will have interdependencies. No significant
primary irritation signal in Study SCD117225 Part 1 would allow initiation of Study SCD117226
Part 1 (single dose application). Once safety, tolerability and exposure information are
determined in Study SCD117226 Part 1, Part 2 of Study SCD117225 may be initiated along with
Part 2 (14-day repeat dose application). No significant cumulative irritation signal (study
SCD117225 Part 2) in combination with adequate 14-day safety (study SCD117226 Part 2) would
allow initiation of Part 3 of Study SCD117225.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01984801
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01984801